Dr. Grignani on the Role of Trabectedin in Sarcoma

Video

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin (Yondelis) as a treatment for patients with sarcoma.

In a phase II study involving patients with metastatic or locally relapsed uterine leiomyosarcoma (MLRUL) pretreated with conventional chemotherapy, trabectedin met the study criteria, with a 6-month progression-free survival (PFS) rate of 33% and a 12-month PFS rate of 20%.

According to Grignani, trabectedin is just one of the many innovative options that oncologists have when dealing with the increasing percentage of patients with this disease. Moreover, he says this patient population is aging, and physicians frequently find elderly patients who have several comorbidities, which can disrupt an otherwise efficacious course of treatment.

Related Videos
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH